Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenvatinib + VIC-1911
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lenvatinib + VIC-1911 is an investigational combination therapy for advanced hepatocellular carcinoma (HCC), particularly in patients who are unresponsive or resistant to lenvatinib monotherapy. Lenvatinib is a small molecule multikinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR1–3), fibroblast growth factor receptors (FGFR1–4), platelet-derived growth factor receptor alpha (PDGFRα), RET proto-oncogene, and KIT proto-oncogene. It inhibits tumor angiogenesis and proliferation. VIC-1911 (also known as TAS-119 or TAS-2104) is a highly selective oral small molecule inhibitor of aurora kinase A (AURKA), which plays a critical role in mitotic spindle formation and cell division; its inhibition leads to cell cycle arrest and apoptosis in cancer cells. The combination aims to overcome resistance mechanisms by targeting both angiogenesis pathways and mitotic regulation[2][3][10].
- Brand names
- Lenvima
- Other names
- lenvatinib + VIC1911
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)AURKA (Aurora kinase A)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR3 (Fibroblast growth factor receptor 3)AURKC (Aurora kinase C)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR2 (Keratinocyte growth factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on lenvatinib + VIC-1911.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenvatinib + VIC-1911.